Novel versatile central line infection reducing device seeks a commercial negotiator/partner or licencing deal.
Resuscitation and intensive care of critically ill patients is not possible without the use of intravascular central venous catheters with 250,000 procedures done in the USA alone.
Unfortunately, central line infections are one of the most common and expensive infections in intensive care. Most devices on the market protect against central line infections for a maximum of 10 days, but for longer dwell times a much more expensive antibiotic coated catheter can be used.
The main problem, however, is that we cannot predict the 25% of patients who require antibiotic-coated catheters. This leads to increased exposure to infection or expensive and painful central line changes for those who stay longer than the average patient.
This inexpensive single-use device is designed to be used with any patient and can theoretically match the efficacy of an antibiotic coated catheter.
The other commercial advantage of this device is it can also be adapted for other procedures (e.g. chest drains, dialysis lines, PICC lines, etc.) therefore vastly extending its marketing potential.
Requirements: Commercial Partner with a proven track record of preparing, conducting and achieving successful contract and licencing deals.
Application deadline: Open